谢小明 - 中山大学 - 肿瘤防治中心

个人简介

在中南大学湘雅医学院于1986年获医学学士学位，1994年获博士学位。1995-1997年在西班牙做博士后，1997-1999年在美国佛罗里达大学做博士后，1999-2003年在美国贝勒医学院任副研究员。2003-2008年在美国德州大学M. D. Anderson癌症中心任研究员，曾任分子和细胞肿瘤系转化研究课题组负责人，2010.9-2010.10在法国让佩林癌症中心合作研究。长期致力于癌症的基因调控，活体成像转基因动物模型和癌症的靶向基因治疗等方面研究，发展了多套新颖的对乳腺癌、胰腺癌、前列腺癌、卵巢癌、肝癌等多种癌症的靶向治疗策略和临床前期产品，与中国、美国、英国、日本、韩国及台湾地区的多家研究机构开展了广泛的交流和合作。

研究领域

1. 乳腺肿瘤的诊断及治疗，乳腺癌干细胞及纳米靶向治疗，乳腺肿瘤分子遗传学 2. 肿瘤学和分子医学（肿瘤的发生发展机制，肿瘤早期诊断与生物治疗等） 3. 细胞生物学 4. 影像医学与生物医学工程 5. 新型实验动物模型

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Gao J, Li L, Wu M, Liu M, Xie X, Guo J, Tang H, Xie X(?). MiR-26a Inhibits Proliferation and Migration of Breast Cancer through Repression of MCL-1. PLoS One. 2013 Jun 4;8(6):e65138. doi: 10.1371/journal.pone.0065138. Print 2013. (IF:4.01) 2. Guo J, Li W, Shi H, Xie X, Li L, Tang H, Wu M, Kong Y, Yang L, Gao J, Liu P, Wei W, Xie X(?). Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Mol Cell Biochem. 2013 Jun 15. [Epub ahead of print]. 3. Kong Y, Wang J, Liu W, Chen Q, Yang J, Wei W, Wu M, Yang L, Xie X, Lv N, Guo J, Li L, Gao J, Xie X(?), Dai S(?). Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients. PLoS One. 2013;8(2):e57092. doi: 10.1371/journal.pone.0057092. (IF:4.01) 4. Li L, Yuan L, Luo J, Gao J, Guo J, Xie X(?). MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med. 2013 May;13(2):109-17..(IF:2.000) 5. Wu MQ, Hu P, Gao J, Wei WD, Xiao XS, Tang HL, Li X, Ge QD, Jia WH, Liu RB, Xie XM(?).Low expression of tyrosine-protein 　　phosphatase nonreceptor type 12 is associated with lymph node metastasis and poor prognosis in operable triple-negative breast cancer. Asian Pac J Cancer Prev. 2013;14(1):287-92. 6. Li L, Xie X, Luo J, Wei W , Xi S, Guo J, Kong Y, Wu M, Gao J, Xie Z, Tang J, Wang X, Yang M, Hung MC, X Xie (?). Targeted Expression of miR-34a by T-VISA System Suppresses Tumor Cell Growth and Invasion in Breast Cancer. Mol Therapy; 2012; 20(12):2326-2334 (IF:6.873) 7. Xie X, L Li, X Xiao, J Guo, Y Kong, M Wu, W Liu, G Gao, J L. Hsu, W Wei, M-C Hung (?) and X Xie(?). Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Mol Cancer Ther.2012 ;11(9);1915-1924. (IF:5.226) 8. Wu M, Wei W, Xiao X, Guo J, Xie X, Li L, Kong Y, Lv N, Jia W, Zhang Y, Xie X(?). Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol. 2012 ; 3240-3249 (IF:2.14) 9. Su Y, Tang LY, Chen LJ, He JR, Su FX, Lin Y, Chen WQ, Xie X(?), Ren ZF(?). Joint Effects of Febrile Acute Infection and an Interferon-γ Polymorphism on Breast Cancer Risk. PLoS One. 2012;7(5):e37275. (IF:4.092) 10. Kong Y, Dai S, Xie X, Xiao X, Lv N, Guo J, Li L, Jia W, Zhang Y, Liu W, Wei W, Xie X(?). High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J Cancer Res Clin Oncol. 2012; 2012;138(2):275-84. (IF:2.558) 11. Lv N, Lin S, Xie Z, Tang J, Ge Q, Wu M, Xie X, Xie X(?)., Wei W(?). Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer. Cancer Epidemiol. 2012;36(4);341-346. (IF:2.010) 12. Xie X, Guo J, Kong Y, Xie GX, Li L, Lv N, Xiao X, Tang J, Wang X, Liu P, Yang M, Xie Z, Wei W, Xie X(?).Targeted expression of E. coli purine nucleoside phosphorylase and Fludara for prostate cancer therapy. J Gene Med. 2011;13:680-691. (IF:3.079) 13. Xie X(?), J.L Hsu, M-G Choi, W Xia, H Yamaguchi, C-T Chen, Z Lu, N T. Ueno, JK. Wolf, RC. Bast, Jr. and M-Ch Hung. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Therapeutics. 2009; 8(8):2375-82. (IF: 5.225). 14. Xie, X(?)., Xia, W., Li, Z., Kuo, H-P.,Liu, Y., Li, Z., Ding, Q., Zhang, S., Spohn, W., Yang, Y., Wei, Y., Lang, J-Y., Evans, D.B., Chiao, P.J., Abbruzzese J.L. and Hung, M-C. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell, 2007;12(July10):52-65. (IF: 26.925). 15. Xie, X(?), Z Luo, KM Slawin, and DM Spencer. The EZC-Prostate Model: Non-invasive prostate imaging in living mice. Mol 　　Endocrinol 2004;18(3):722-732. (IF:5.389). 16. Xie X(?), X Zhou, Y Liu, K Slawin, and D Spencer. Adenovirus-mediated tissue-targeted expression of a caspase 9-based artificial death switch for the treatment of prostate cancer. Cancer Res 2001; 61: 6795-804. (IF: 8.234). 17. Xie X(?), X Zhao, Y Liu, CYF Young, DJ Tindall, K Slawin, and D Spencer. Robust prostate-specific expression for targeted gene therapy based on human kallikrein 2 (hK2) promoter. Human Gene Therapy 2001;12(5): 549-61. (IF: 4.829). 18. Xie X(?), CE Forsmark, and JY Lau. Effect of bile and pancreatic juice on adenovirus-mediated gene delivery: Implications on the feasibility of gene delivery through ERCP. Digestive Diseases and Sciences 2000; 45(2):230-36. (IF:1.583). 19. Zhang B, Song Q, Zhang B, Tang Z, Xie X, Yang H, He J, Li H, Li J, Li J, Fan J, Huang R, Zhang H, Qiao Y. A 10-year (1999 ～ 2008) retrospective multi-center study of breast cancer surgical management in various geographic areas of China. Breast. 2013 Feb 4. doi:pii: S0960-9776(13)00006-4. 10.1016/j.breast.2013.01.004. [Epub ahead of print].